Kineta, Inc. Files Q1 2025 10-Q with Key Agreements
| Field | Detail |
|---|---|
| Company | Kineta, Inc./De |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, agreements, financials
TL;DR
Kineta's Q1 25 10-Q is in, shows Kenny separation agreement & other deals. Check financials.
AI Summary
Kineta, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including references to a Kenny Separation Agreement as of March 31, 2025, and various agreements such as a Securities Purchase Agreement and a Sublease Agreement from 2024. The company, formerly known as Yumanity Therapeutics, Inc., is involved in the pharmaceutical preparations sector.
Why It Matters
This filing provides insight into Kineta's financial health and ongoing business activities, including executive separation agreements and significant contractual arrangements, which are crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: medium — The filing is a standard quarterly report, but the presence of separation agreements and various other contracts suggests potential restructuring or significant operational changes that could impact the company's risk profile.
Key Numbers
- 20250331 — Reporting Period End Date (Marks the end of the fiscal quarter covered by the report.)
- 2024 — Year of Key Agreements (Indicates the timeframe for significant agreements like the Securities Purchase and Sublease Agreements.)
Key Players & Entities
- Kineta, Inc. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- Kenny Separation Agreement (agreement) — Specific agreement mentioned
- Yumanity Therapeutics, Inc. (company) — Former company name
- Securities Purchase Agreement (agreement) — Contractual agreement
- Sublease Agreement (agreement) — Contractual agreement
FAQ
What is the nature of the Kenny Separation Agreement mentioned in the filing?
The filing references a 'KennySeparationAgreementMember' as of March 31, 2025, but does not provide specific details on the terms or financial implications of this agreement within the provided text.
What were the key financial activities or results for Kineta, Inc. in the quarter ending March 31, 2025?
The provided text is an excerpt from the 10-Q filing and does not contain specific financial results such as revenue, net income, or cash flow for the quarter ending March 31, 2025.
What is the business address of Kineta, Inc.?
Kineta, Inc.'s business address is 7683 SE 27TH STREET, SUITE 481, MERCER ISLAND, WA 98040.
What industry does Kineta, Inc. operate in?
Kineta, Inc. operates in the Pharmaceutical Preparations industry, with the Standard Industrial Classification code 2834.
What were Kineta, Inc.'s former company names?
Kineta, Inc. was formerly known as Yumanity Therapeutics, Inc. and Proteostasis Therapeutics, Inc.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding KINETA, INC./DE.